Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day
Herantis Pharma Plc, Press Release, 5 October 2022 at 15:30 EEST Herantis Pharma Plc (“Herantis”), developing disease modifying therapies for Parkinson’s disease, today announced that CEO Antti Vuolanto and CSO Henri Huttunen will be attending and holding 1x1 meetings at Bio-Europe 2022 between October 24th–26th, 2022. Additionally, CEO Antti Vuolanto will be attending, presenting, and participating in a CNS panel discussion at Redeyes’ Theme: Neurology Day on October 12th, 2022. Conference Details: Redeye Theme: Neurology Date: October 12th, 2022 Webcast Link: